Related Experiment Video

Updated: May 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin

Ping Zhang1, András Gruber, Shogo Kasuda

  • 1Hemostasis & Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA.

Circulation
|June 19, 2012
PubMed

Insights

A novel PAR1 inhibitor, PZ-128, effectively reduces platelet activation and thrombosis during percutaneous coronary intervention without impacting hemostasis. This new therapeutic offers rapid, reversible platelet inhibition for acute coronary syndromes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Percutaneous coronary intervention (PCI) heightens thrombin-dependent platelet activation, increasing arterial thrombosis risk and myocardial necrosis in acute coronary syndromes.
  • Existing treatments face challenges with adverse effects, highlighting the need for novel therapeutics targeting platelet activation while preserving hemostasis.
  • The protease-activated receptor 1 (PAR1) is a key mediator of thrombin signaling and an emerging target for antiplatelet therapy.

Purpose of the Study:

  • To develop and characterize a first-in-class intracellular PAR1 inhibitor (PZ-128) for use in PCI.
  • To evaluate the pharmacokinetic properties, efficacy, and safety of PZ-128 in preclinical models.

Main Methods:

  • Development of PZ-128, a cell-penetrating pepducin targeting the PAR1 receptor-G-protein interface.
  • Assessment of PZ-128's rapid onset, platelet aggregation suppression, and anti-thrombotic effects in guinea pigs and baboons.
  • Evaluation of PZ-128's impact on bleeding and coagulation parameters in primates and human blood samples.

Main Results:

  • PZ-128 demonstrated rapid onset of action, suppressing PAR1-mediated platelet aggregation and arterial thrombosis in vivo.
  • The inhibitor showed strong synergy with clopidogrel and full recovery of platelet function within 24 hours.
  • Crucially, PZ-128 did not affect bleeding or coagulation parameters in primates or human blood, indicating a favorable safety profile.

Conclusions:

  • PZ-128 exhibits potent antiplatelet activity with a rapid onset and reversible effect, suitable for acute PCI settings.
  • The lack of adverse effects on hemostasis suggests PZ-128 may offer a safer alternative to existing PAR1 inhibitors.
  • PZ-128 represents a promising therapeutic candidate for managing platelet activation in patients undergoing PCI for acute coronary syndromes.
Abstract

More Related Videos

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

3.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K

Related Concept Videos

Paracrine Signaling01:21

Paracrine Signaling

Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...
50.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
225